Targeting tryptophan availability to tumors: the answer to immune escape?
Author
Badawy, Abdulla
Date
2018-06-10Acceptance date
2018-05-13
Type
Article
Publisher
Wiley
ISSN
1440-1711
Metadata
Show full item recordAbstract
Tumoral immune escape is an obstacle to successful cancer therapy. Tryptophan (Trp) metabolites along the kynurenine pathway induce immunosuppression involving apoptosis of effector immune cells, which tumors use to escape an immune response. Production of these metabolites is initiated by indoleamine 2,3‐dioxygenase (IDO1). IDO1 inhibitors, however, do not always overcome the immune escape and another enzyme expressed in tumors, Trp 2,3‐dioxygenase (TDO2), has been suggested as the reason. However, without Trp, tumors cannot achieve an immune escape through either enzyme. Trp is therefore key to immune escape. In this perspective paper, Trp availability to tumors will be considered and strategies limiting it proposed. One major determinant of Trp availability is the large increase in plasma free (non‐albumin‐bound) Trp in cancer patients, caused by the low albumin and the high non‐esterified fatty acid (NEFA) concentrations in plasma. Albumin infusions, antilipolytic therapy or both could be used, if indicated, as adjuncts to immunotherapy and other therapies. Inhibition of amino acid uptake by tumors is another strategy and α‐methyl‐DL‐tryptophan or other potential inhibitors could fulfill this role. Glucocorticoid receptor antagonists may have a role in preventing glucocorticoid induction of TDO in host liver and tumors expressing it and in undermining the permissive effect of glucocorticoids on IDO1 induction by cytokines. Nicotinamide may be a promising TDO2 inhibitor lacking disadvantages of current inhibitors. Establishing the Trp disposition status of cancer patients and in various tumor types may provide the information necessary to formulate tailored therapeutic approaches to cancer immunotherapy that can also undermine tumoral immune escape.
Journal/conference proceeding
Immunology and Cell Biology;
Citation
Badawy, A.A.B. (2018) 'Targeting tryptophan availability to tumors: the answer to immune escape?', Immunology and Cell Biology, 96(10), pp.1026-1034. DOI: 10.1111/imcb.12168.
Description
Article published by Immunology and Cell Biology on 19 November 2018, available at: https://doi.org/10.1111/imcb.12168.
Sponsorship
Cardiff Metropolitan University (Grant ID: Cardiff Metropolian (Internal))
Collections
Related items
Showing items related by title, author, subject and abstract.
-
The effect of Daidzein in modulating an anti-inflammatory immune response in breast cancer.
Jeevakumar, Nirusha (Cardiff Metropolitan University, 2017-06-01)Aim and background: The aim of this study was to determine the role of Daidzein in modulating the immune response in the breast cancer cell line, MDA-MB-231, through assessing its effect on the cytokines IL-6 and ... -
TLR-dependent hepcidin expression by THP-1 cells in response to TLR4 and TLR9 (LPS and CpG)
Al-Lawati, Hiba Abdul Redha (Cardiff Metropolitan University, 2011)Linking immunity with iron can be well illustrated by the production of hepcidin as it is considered to be the master regulator of iron metabolism in mammals. Iron is an essential element for microbes and higher animals ... -
The effect of manuka honey organic extract on secretion of TNF-alpha alpha ans IL-8 from human monocytes
Nidimamidi, Giridhar (Cardiff Metropolitan University, 2006)Since the times immemorial, honey has been used as a therapeutic agent to aid in wound healing. Honey possesses unknown substances that make it antibacterial and capable of stimulating the immune response. Though there is ...